Newsroom 2015
Everything BrainStorm published in 2015.
Latest from BrainStorm
BrainStorm Reschedules Corporate Update Conference Call to January 11, 2016
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has rescheduled its conference call, originally scheduled for Wednesday, December 16, 2015 to Monday, January 11, 2016, due to longer than exp
BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Dr. Revital Geffen-Aricha, M.Sc., Ph.D., as Vice President of Research and Development. Dr. Geffen-Aricha will be based in Israe
BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will hold a conference call on Wednesday, December 16, 2015 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST). Mr. Ch
BrainStorm and Octane Biotech Announce Success in Cocoon™ Application Development Based on Customized Bioreactor for NurOwn® Stem Cells
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian company that focuses on clinical systems for cell and tissue therapy, announced today that they have made significant progress towa
BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israel's Office of the Chief Scientist
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an additional grant of approximately $735,000 from Israel's Offi
BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter ended September 30, 2015.
BrainStorm Cell Therapeutics Announces Positive DSMB Review in Phase 2 Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Data and Safety Monitoring Board (DSMB) conducted its second pre-planned safety review of the randomized, double-blind, placebo-controlled ph
BrainStorm Strengthens Intellectual Property Position - Granted Patent for Company's NurOwn Technology Platform
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company has been granted a patent by the Israeli Patent Office for BrainStorm's application, titled "Isolated Population of Cells, Methods of
BrainStorm Cell Therapeutics' Chief Scientific Advisor to Present At The 2015 FENS-RM in Thessaloniki, Greece
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announces that its Chief Scientific Advisor, Prof Daniel Offen, PhD, will be presenting today at the 2015 Federation Of European Neuroscience Societies (FENS) Regional
BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS Trial
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the final patient has been treated in its multicenter Phase 2 clinical trial investigating the company's proprietary NurOwn™ stem cell technology
BrainStorm Cell Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California. Tony Fiorino, MD, PhD, wi
BrainStorm Announces Appointment of Chaim Lebovits as Chief Executive Officer
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Mr. Chaim Lebovits, who has been serving as the Company's President since July 2007, as Chief Executive Officer (CEO). Mr. Lebov
BrainStorm Cell Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at the Rodman & Renshaw 17th Annual Global Investment Conference s
BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2015.
BrainStorm Cell Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has completed enrollment in its ongoing randomized, double-blind placebo-controlled phase 2 clinical trial of NurOwn in amyotrophic lateral s
BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report second quarter 2015 financial results on Thursday, August 13, 2015. The Company will issue a press release before the market opens
BrainStorm Strengthens Executive Team: Announces the Appointment of Yoram Bibring as Chief Financial Officer
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Yoram Bibring as Chief Financial Officer, effective July 30, 2015. Mr. Bibring will be responsible for all corporate finance and
BrainStorm Cell Therapeutics to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at Cantor Fitzgerald's Inaugural Healthcare Conference on Wednesda
BrainStorm Cell Therapeutics Added to Russell Microcap® Index
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that has been added to the Russell Microcap® Index. The Russell indexes are reconstituted on an annual basis, with this year's process having conclude
BrainStorm Cell Therapeutics at the BIO International Convention
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is participating in the Israel Pavilion at the invitation of Israel's Office of the Chief Scientist. BrainStorm is one of a small group of Israeli biopharmaceutical,
BrainStorm Cell Therapeutics Announces First Quarter 2015 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.
BrainStorm Cell Therapeutics to Present at Upcoming Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Yael Gothelf, Vice President, Scientific and Regulatory Affairs, will be presenting at the at IATI Biomed 2015 Conference and ISCT 2015 Annua
BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report first quarter 2015 financial results on Thursday, May 14, 2015. The Company will issue a press release before the market opens and
BrainStorm's NurOwn Demonstrates a Statistically Significant Effect in ALS Patients
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis (ALS) at a poster session today at the American Academy of Neurology annual
BrainStorm Cell Therapeutics to Present Positive NurOwn Phase 2a Clinical Data at American Academy of Neurology Annual Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Acade
BrainStorm Announces Financial Results for 2014 and Provides Business Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.
BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015. The Company will issue a press release before the
BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that CEO Tony Fiorino, MD, PhD, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 in New York City.
BrainStorm Receives Notice of Allowance for its NurOwn™ Technology Platform from Israel's Patent Office
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from Israel's Patent Office for its patent application titled "Isolated Population of Cells, Methods of Gen
BrainStorm CEO to Present at the 17th Annual BIO CEO & Investor Conference
HACKENSACK, N.J. & PETACH TIKVAH, Israel, Feb. 4, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chief Executive Officer Tony Fiorino, MD, PhD, will be presenting a corpor
BrainStorm Announces Positive DSMB Recommendation in Ongoing Phase 2 Trial with NurOwn™ in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Data and Safety Monitoring Board (DSMB) met to conduct its first safety review of the randomized, double-blind, placebo-controlled phase 2 cli
BrainStorm Announces Exceptional Preclinical Results of NurOwn™ in Mouse Autism Model
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive results from preclinical studies of NurOwn™ in the BTBR mouse model of autism. NurOwn™ cells are mesenchymal stem cells (MSCs) that have been
BrainStorm Enters Into Warrant Exercise Agreement for Approximately $13 Million in Proceeds
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise Agreement with certain holders of warrants issued in the June 13, 2014 private placement. These holders have ag
BrainStorm Announces Receipt of Approximately $3.1 Million from Warrant Exercises
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that since January 2, 2015 it has received approximately $3.1 million from the exercise of warrants for approximately 700 thousand shares, which were
BrainStorm CEO to Present at Two Upcoming Investor Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Tony Fiorino, MD, PhD, Chief Executive Officer, will be presenting at two upcoming investor conferences.
BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn™
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadas
No press releases match that search. Try a shorter phrase, or clear the field to see the full list.
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.